) presented multiple analyses from several clinical studies on
its lead product, Jakafi, at the 2013 American Society of
Hematology (ASH) annual meeting. Results revealed that Jakafi was
effective in improving overall survival in patients suffering
from myelofibrosis (MF).
ACORDA THERAPT (ACOR): Free Stock Analysis
ACTELION LTD (ALIOF): Get Free Report
INCYTE CORP (INCY): Free Stock Analysis
NOVARTIS AG-ADR (NVS): Free Stock Analysis
To read this article on Zacks.com click here.
Incyte presented data from a three-year follow-up analysis from
COMFORT-I and a pooled analysis of the two COMFORT studies on
Jakafi. Results showed that spleen volume reductions were
maintained in patients treated with Jakafi compared to those
under placebo and best available therapy. Overall survival also
improved in Jakafi treated patients compared to those treated
with placebo and the best available therapy.
Results from a separate retrospective analysis revealed that
treatment with Jakafi may reduce the risk of death by
approximately 50% in comparison to conventional therapies.
Moreover, an exploratory analysis of data collected over five
years from a phase II study showed that Jakafi may
stabilize/improve bone marrow fibrosis in patients suffering from
We note that Jakafi is the first and only approved treatment for
patients suffering from intermediate or high-risk MF in the U.S.
Jakafi (ex-U.S. trade name: Jakavi) is marketed by
) outside the U.S. The drug is also approved by the European
Commission to treat adults suffering from primary MF,
post-polycythemia vera MF or post-essential thrombocythemia MF.
Incyte is looking to expand the drug's label in other oncology
indications as well.
Incyte recorded net product revenues of approximately $60.2
million from Jakafi sales in the third quarter of 2013, up 37.8%
year over year. We expect investor focus to remain on Jakafi
Incyte also announced positive data from an interim analysis of a
phase II study (n>85) on INCB39110 at the 2013 ASH annual
meeting. INCB39110 is being developed for the treatment of
patients suffering from intermediate or high-risk MF. Results
revealed that meaningful improvements were observed in MF-related
symptoms, including those associated with splenomegaly, in
patients treated with INCB39110. We are encouraged by the
company's progress with its pipeline.
Incyte, a biopharmaceutical company, currently carries a Zacks
Rank #3 (Hold). Some better ranked stocks in the bio pharma
Acorda Therapeutics, Inc.
). While Actelion holds a Zacks Rank #1 (Strong Buy), Acorda
carries a Zacks Rank #2 (Buy).